Key terms
About KRON
Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KRON news
Mar 26
6:40am ET
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)
Mar 22
2:01am ET
Kronos Bio’s Restructuring Risks: Cost Cuts Versus Operational Efficiency
Mar 21
7:10am ET
Kronos Bio reports Q4 EPS (43c), consensus (52c)
Mar 07
4:36pm ET
Kronos Bio announces restructuring, including 21% reduction in work-force
Mar 07
4:26pm ET
Kronos Bio Implements Workforce Reduction to Extend Financial Runway
Mar 06
7:37am ET
Piper Sandler Remains a Buy on Kronos Bio (KRON)
Jan 29
12:02pm ET
Kronos Bio treatment of AML granted FDA orphan designation
Jan 26
6:18am ET
Buy Rating Affirmed for Kronos Bio Amid Restructuring and Promising KB-0742 Clinical Data
Jan 26
4:12am ET
Kronos Bio Announces Top-Level Executives’ Departure
Jan 26
4:12am ET
Kronos Bio Announces Executive Leadership Changes and Severance Deals
Jan 25
8:20am ET
Kronos implements new leadership structure, eliminates CMO, CSO, COO roles
No recent press releases are available for KRON
KRON Financials
Key terms
Ad Feedback
KRON Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KRON Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
